Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy

Biomaterials

Volumn 91, Issue , 2016, Pages 1-10

  Jaskula Sztul, Renata ^a   Xu, Wenjin ^b   Chen, Guojun ^b   Harrison, April ^a   Dammalapati, Ajitha ^a   Nair, Renu ^a   Cheng, Yiqiang ^c   Gong, Shaoqin ^b   Chen, Herbert ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Wisconsin Electric Machines and Power Electronics Consortium   (United States)

^c UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Histone deacetylase inhibitor; Neuroendocrine cancer; Octreotide; Targeted drug delivery; Thailandepsin A; Unimolecular micelles

Indexed keywords

BLOCK COPOLYMERS; DENDRIMERS; DISEASES; ONCOLOGY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS;

HISTONE DEACETYLASE INHIBITOR; NEUROENDOCRINE CANCER; OCTREOTIDE; TARGETED DRUG DELIVERY; UNIMOLECULAR MICELLES;

MICELLES;

AMPHOPHILE; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; MACROGOL; NANOCARRIER; OCTREOTIDE; POLYLACTIDE; THAILANDEPSIN A; TRANSCRIPTION FACTOR MASH1; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DEPSIPEPTIDE; DRUG CARRIER; LACTIC ACID DERIVATIVE; MACROGOL DERIVATIVE; MICELLE; POLY(LACTIC ACID-ETHYLENE GLYCOL);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARBOXYLATION; CARCINOID; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG CONJUGATION; ENDOCYTOSIS; ENDOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MICELLIZATION; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CARCINOMA, NEUROENDOCRINE; CHEMISTRY; DRUG DELIVERY SYSTEM; MICELLE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; DEPSIPEPTIDES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LACTATES; MALE; MICE, NUDE; MICELLES; OCTREOTIDE; POLYETHYLENE GLYCOLS;

EID: 84961928059     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.03.010     Document Type: Article

References (51)

1. Roy M., Chen H., Sippel R.S. Current understanding and management of medullary thyroid cancer. Oncologist 2013, 18:1093-1100.
2. Pinchot S.N., Kunnimalaiyaan M., Sippel R.S., Chen H. Medullary thyroid carcinoma: targeted therapies and future directions. J. Oncol. 2009, 2009.
3. Pinchot S.N., Holen K., Sippel R.S., Chen H. Carcinoid tumors. Oncol. 2008, 13:1255-1269.
4. Modlin I.M., Oberg K., Chung D.C., Jensen R.T., de Herder W.W., Thakker R.V., et al. Gastroenteropancreatic neuroendocrine tumours. lancet Oncol. 2008, 9:61-72.
5. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., et al. One hundred years after "Carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008, 26:3063-3072.
6. Isozaki T., Kiba T., Numata K., Saito S., Shimamura T., Kitamura T., et al. Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. Intern Med. 1999, 38:17-21.
7. Brown K.T., Koh B.Y., Brody L.A., Getrajdman G.I., Susman J., Fong Y., et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J. Vasc. Interv. Radiol. 1999, 10:397-403.
8. D.C. Metz, R.T. Jensen. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology, 135:1469-1492.
9. Kunz P.L., Reidy-Lagunes D., Anthony L.B., Bertino E.M., Brendtro K., Chan J.A., et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013, 42:557-577.
10. Chan J., Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr. Treat. Options Oncol. 2014, 15:365-379.
11. Ning L., Jaskula-Sztul R., Kunnimalaiyaan M., Chen H. Suberoyl bishydroxamic acid activates Notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann. Surg. Oncol. 2008, 15:2600-2605.
12. Jaskula-Sztul R., Eide J., Tesfazghi S., Dammalapati A., Harrison A.D., Yu X.M., et al. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction. Mol. Cancer Ther. 2015, 14:499-512.
13. Greenblatt D.Y., Vaccaro A.M., Jaskula-Sztul R., Ning L., Haymart M., Kunnimalaiyaan M., et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007, 12:942-951.
14. Wilson A.J., Cheng Y.Q., Khabele D. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. J. Ovarian Res. 2012, 5.
15. Weinlander E., Somnay Y., Harrison A.D., Wang C., Cheng Y.Q., Jaskula-Sztul R., et al. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. J. Surg. Res. 2014, 190:191-197.
16. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nano 2007, 2:751-760.
17. Cabral H., Nishiyama N., Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Accounts Chem. Res. 2011, 44:999-1008.
18. Zhao B., Zhao Y., Huang Y., Luo L., Song P., Wang X., et al. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials 2012, 33:2508-2520.
19. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
20. Xiao L., Xiong X., Sun X., Zhu Y., Yang H., Chen H., et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 2011, 32:5148-5157.
21. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
22. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 2006, 112:630-648.
23. Gong C., Deng S., Wu Q., Xiang M., Wei X., Li L., et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 2013, 34:1413-1432.
24. ® H40, poly(l-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery. Biomaterials 2009, 30:3009-3019.
25. Xu W.J., Burke J.F., Pilla S., Chen H., Jaskula-Sztul R., Gong S.Q. Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale 2013, 5:9924-9933.
26. Xu W., Siddiqui I.A., Nihal M., Pilla S., Rosenthal K., Mukhtar H., et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 2013, 34:5244-5253.
27. Pang X.C., Zhao L., Han W., Xin X.K., Lin Z.Q. A general and robust strategy for the synthesis of nearly monodisperse colloidal nanocrystals. Nat. Nanotechnol. 2013, 8:426-431.
28. Guo J.T., Hong H., Chen G.J., Shi S.X., Zheng Q.F., Zhang Y., et al. Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles. Biomaterials 2013, 34:8323-8332.
29. Guo J.T., Hong H., Chen G.J., Shi S.X., Nayak T.R., Theuer C.P., et al. Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging. ACS Appl. Mater Inter 2014, 6:21769-21779.
30. Chen G., Wang L., Cordie T., Vokoun C., Eliceiri K.W., Gong S. Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging. Biomaterials 2015, 47:41-50.
31. Li X., Qian Y., Liu T., Hu X., Zhang G., You Y., et al. Amphiphilic multiarm star block copolymer-based multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging. Biomaterials 2011, 32:6595-6605.
32. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials 2009, 30:5757-5766.
33. Wang C., Henkes L.M., Doughty L.B., He M., Wang D., Meyer-Almes F.J., et al. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J. Nat. Prod. 2011, 74:2031-2038.
34. Yang X.Q., Grailer J.J., Pilla S., Steeber D.A., Gong S.Q. Tumor-targeting, pH-responsive, and stable unimolecular micelles as drug nanocarriers for targeted cancer therapy. Bioconjugate Chem. 2010, 21:496-504.
35. Kreutzer G., Ternat C., Nguyen T.Q., Plummer C.J.G., Månson J.-A.E., Castelletto V., et al. Water-soluble, unimolecular containers based on amphiphilic multiarm star block copolymers. Macromolecules 2006, 39:4507-4516.
36. Speelmans G., Staffhorst R.W.H.M., Dekruijff B., Dewolf F.A. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma-membrane. Biochemistry 1994, 33:13761-13768.
37. Lee Y., Park S.Y., Mok H., Park T.G. Synthesis, characterization, antitumor activity of pluronic mimicking copolymer micelles conjugated with doxorubicin via acid-cleavable linkage. Bioconjugate Chem. 2008, 19:525-531.
38. Gillies E.R., Fréchet J.M.J. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjugate Chem. 2005, 16:361-368.
39. Xiao Y., Jaskula-Sztul R., Javadi A., Xu W., Eide J., Dammalapati A., et al. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 2012, 4:7185-7193.
40. Sun M.J., Wang Y., Shen J., Xiao Y.Y., Su Z.G., Ping Q.N. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Nanotechnology 2010, 21.
41. Huo M., Zou A., Yao C., Zhang Y., Zhou J., Wang J., et al. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 2012, 33:6393-6407.
42. Kamba S.A., Ismail M., Hussein-Al-Ali S.H., Ibrahim T.A.T., Zakaria Z.A. In vitro delivery and controlled release of doxorubicin for targeting osteosarcoma bone cancer. Molecules 2013, 18:10580-10598.
43. Oberg K., Janson E.T., Eriksson B. Tumour markers in neuroendocrine tumours. Ital. J. Gastroenterol. Hepatol. 1999, 31. S160-S2.
44. Chen H., Udelsman R., Zeiger M.A., Ball D.W. Human achaete-scute homolog-1 is highly expressed in a subset of neuroendocrine tumors. Oncol. Rep. 1997, 4:775-778.
45. K-i Ogawara, Yoshizawa Y., Un K., Araki T., Kimura T., Higaki K. Nanoparticle-based passive drug targeting to tumors: considerations and implications for optimization. Biol. Pharm. Bull. 2013, 36:698-702.
46. Bertrand N., Wu J., Xu X.Y., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Del Rev. 2014, 66:2-25.
47. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
48. MacEwan S.R., Callahan D.J., Chilkoti A. Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond) 2010, 5:793-806.
49. Fang J., Sawa T., Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv. Exp. Med. Biol. 2003, 519:29-49.
50. Wängberg B., Nilsson O., Johanson V., Kölby L., Forssell-Aronsson E., Andersson P., et al. Somatostatin receptors in the diagnosis and therapy of neuroendocrine tumors. Oncologist 1997, 2:50-58.
51. Ono K., Suzuki T., Miki Y., Taniyama Y., Nakamura Y., Noda Y., et al. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res. 2007, 27:2231-2239.